Newron Pharmaceuticals S.p.A. Secures Up to €38 Million to Accelerate Phase III Evenamide Program in Treatment-Resistant Schizophrenia

Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the p...

February 18, 2026 | Wednesday | News
Sapu Bioscience Secures Global IP Fortress for OT-101, Advancing Integrated CNS Platform in Neurology and Oncology

Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...

February 18, 2026 | Wednesday | News
InnoCare Pharma Doses First Patient in Phase II/III Trial of Soficitinib for Chronic Spontaneous Urticaria

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced &nb...

February 17, 2026 | Tuesday | News
MEDIPOST Inc. Files IND Amendment to Advance Phase III Stem Cell Therapy Trial for Knee Osteoarthritis

MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative disea...

February 16, 2026 | Monday | News
Apimeds and Lōkahi Therapeutics Secure FDA Type C Meeting for LT-100 in Osteoarthritis

Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Ad...

February 13, 2026 | Friday | News
Novocure Advances Pancreatic Cancer Care with FDA Approval of Optune Pax®

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic...

February 13, 2026 | Friday | News
CEO Daniel O’Day Underscores Strength of Gilead’s HIV Franchise After Solid 2025 Results

  Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $1...

February 12, 2026 | Thursday | Company results
Bayer’s Asundexian Reduces Recurrent Stroke Risk by 26 Percent in Landmark Phase III Trial

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...

February 10, 2026 | Tuesday | News
Bristol Myers Squibb Partners with Evinova to Advance AI Driven Clinical Trial Optimization

Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency ...

February 10, 2026 | Tuesday | News
Peijia Medical Advances Global Expansion with EU MDR CE Mark Filing for GeminiOne TEER System

Peijia Medical Limited announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application fo...

February 10, 2026 | Tuesday | News
Eisai’s Leqembi Autoinjector Clears Key Regulatory Step in China for Early Alzheimer’s Treatment

BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced  that the Biologics License Application (BLA) for the treatme...

February 10, 2026 | Tuesday | News
Geneoscopy Strengthens Diagnostic Market Position After USPTO Invalidates Exact Sciences Patent Claims

Decision removes last patent hurdle as Geneoscopy advances ColoSense®, its RNA-based noninvasive colorectal cancer screening test Geneosco...

February 09, 2026 | Monday | News
Novartis Expands US Innovation Footprint with USD 23 Billion R&D Push, Including New San Diego Research Hub

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including C...

February 09, 2026 | Monday | News
Slingshot Biosciences Strengthens UK and EU Presence with Synthetic Cell Mimic Technology

Life sciences innovator and leader in precision-engineered synthetic cell mimic technology expands its UK/EU operations to accelerate cell and gene thera...

February 06, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close